• Arctic Bioscience expects solid sales growth in Q4 2026, supported by a robust Nutra order pipeline and recurring customers.
• Nine-month Nutra revenue rose 26% to NOK 32.6 million; third-quarter revenue increased approximately 7% to NOK 9.3 million.
• Supplier delivery delays continue to affect revenue timing, with diversified sourcing a priority.
• Further pharmaceutical development is expected to be financed separately, with partnerships and liquidity discipline remaining priorities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Arctic Bioscience AS published the original content used to generate this news brief on November 11, 2026, and is solely responsible for the information contained therein.